Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Myriad Genetics Inc

MYGN
Current price
15.25 USD -0.55 USD (-3.48%)
Last closed 15.68 USD
Company myriad.com
ISIN US62855J1043
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 1 581 183 104 USD
Yield for 12 month -11.39 %
1Y
3Y
5Y
10Y
15Y
MYGN
21.11.2021 - 28.11.2021

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah. Address: 322 North 2200 West, Salt Lake City, UT, United States, 84116

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

26.86 USD

P/E ratio

Dividend Yield

Current Year

+753 200 000 USD

Last Year

+678 400 000 USD

Current Quarter

+211 500 000 USD

Last Quarter

+202 200 000 USD

Current Year

+517 000 000 USD

Last Year

+476 400 000 USD

Current Quarter

+147 100 000 USD

Last Quarter

+137 600 000 USD

Key Figures MYGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -40 700 000 USD
Operating Margin TTM -8.35 %
PE Ratio
Return On Assets TTM -5.35 %
PEG Ratio 1.4001
Return On Equity TTM -16.4 %
Wall Street Target Price 26.86 USD
Revenue TTM 823 600 000 USD
Book Value 8.04 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 11.2 %
Dividend Yield
Gross Profit TTM 476 400 000 USD
Earnings per share -1.77 USD
Diluted Eps TTM -1.77 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -14.09 %

Dividend Analytics MYGN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History MYGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 2:1
Payout Ratio
Last Split Date 26.03.2009
Dividend Date

Stock Valuation MYGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 476.1905
Enterprise Value Revenue 2.0284
Price Sales TTM 1.9198
Enterprise Value EBITDA -23.4699
Price Book MRQ 2.1353

Financials MYGN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators MYGN

For 52 weeks

16.61 USD 29.3 USD
50 Day MA 24.54 USD
Shares Short Prior Month 4 190 757
200 Day MA 23.74 USD
Short Ratio 6.48
Shares Short 4 494 424
Short Percent 6.93 %